![]() Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Refereed |
Title | Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. |
Journal | Formal name:European journal of gastroenterology & hepatology ISSN code:14735687/0954691X |
Domestic / Foregin | Foregin |
Volume, Number, Page | 34,pp.698-706 |
Papers・Author | Tada, Toshifumia; Kumada, Takashib; Hiraoka, Atsushic; Hirooka, Masashid; Kariyama, Kazuyae; Tani, Jojif; Atsukawa, Masanorig; Takaguchi, Koichih; Itobayashi, Eii; Fukunishi, Shinyaj; Tsuji, Kunihikok; Ishikawa, Torul; Tajiri, Kazutom; Ochi, Hironorin; Yasuda, Satoshio; Toyoda, Hidenorio; Ogawa, Chikarap; Nishimura, Takashi; Hatanaka, Takeshir; Kakizaki, Satorus; Shimada, Noritomot; Kawata, Kazuhitou; Tanaka, Takaakic; Ohama, Hidekoj; Nouso, Kazuhiroe; Morishita, Asahirof; Tsutsui, Akemih; Nagano, Takuyah; Itokawa, Noriog; Okubo, Tomomig; Arai, Taeangg; Imai, Michitakal; Naganuma, Atsushiv; Koizumi, Yoheid; Nakamura, Shinichiroa; Joko, Koujin; Iijima, Hiroko Hiasa, Yoichid; On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group |
Publication date | 2022/06 |